The largest database of trusted experimental protocols

Pd0325901 s1036

Manufactured by Selleck Chemicals
Sourced in United States

PD0325901 (S1036) is a small molecular compound that functions as a selective, reversible, and ATP-competitive inhibitor of the MEK1/2 enzyme. It is commonly used in cell culture experiments as a research tool to study the Ras/MAPK signaling pathway.

Automatically generated - may contain errors

4 protocols using pd0325901 s1036

1

Comprehensive Antibody Panel for EMT Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies against HMGB3 (27465-1-AP), ETS-1 (12118-1-AP), MEK1/2 (11049-1-AP), CCND1 (60186-1-Ig), c-Myc (10828-1-AP), SOX2 (11064-1-AP), and ALDH1A1 (15910-1-AP) were purchased from Proteintech (Wuhan, China). Antibodies for p-MEK1/2 (9154), p-ERK1/2 (4370), and an Epithelial-Mesenchymal Transition Antibody Sampler Kit (9782) were obtained from Cell Signaling Technology (Danvers, MA, USA). Antibody against ERK1/2 (ab17942) was obtained from Abcam (Cambridge, UK). Antibody against β-actin (A5441) was purchased from Sigma-Aldrich (St. Louis, MO, USA). AZD6244 (S1008) and PD0325901 (S1036) were acquired from Selleck Chemicals (Houston, TX, USA).
+ Open protocol
+ Expand
2

Establishing Cell Lines for Nf1 Tumorigenesis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell lines, established from tumors arising in irradiated Nf1+/− F1 mice (17 (link)). Early passage stocks were established for all cell lines and experimental cells were drawn from these stocks approximately every twenty to thirty passages. Mycoplasma testing was done approximately yearly. Inhibitors were purchased from Selleck Chemicals (PD0325901 S1036, Everolimus (RAD001) S1120, Dactolisib (BEZ235) S1009, PD184352 (CI-1040) S1020, Torkinib (PP242) S2218, PIK-75 HCl S1205, Tozasertib (VX680) S1048, Barasertil (AZD1152) S1147, Alisertib (MLN8237) S1133, Binimetinib (MEK162) S7007, Trametinib (GSK1120212) S2673, Rapamycin (Sirolimus) S1039). Drug-resistant cell lines 989 PD_R, 989 RAD_R, 881 PD_R and 881 RAD_R were derived from each original parental cell line by continuous exposure to PD0325901 or RAD001. Cell lines 989 and 881 were exposed to increasing concentrations (from 25 nM to 500 nM) of PD0325901 or RAD001 for six months. Resistant cell lines were continuously maintained in medium supplemented with inhibitor. For drug washout experiments, cells were washed twice with PBS, inhibitors were withdrawn for 12 days and further analyses performed.
+ Open protocol
+ Expand
3

Drosophila Genetics for Tumor Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
Crosses were set up with esg-GAL4, tub-GAL80TS, UAS-GFP and UAS-yki3SA or UAS-dERKSEM; UAS-yki3SA at 18°C to inactivate GAL4. 4-day-old adult progenies were placed at 29°C to induce the transge nes. For the in vivo RNAi screening of ligands in yki3SA-tumor guts, different RNAi lines were crossed to esg-GAL4, tub-GAL80TS, UAS-GFP/CyO; UAS-yki3SA/TM6B at 18 °C . Virgin progenies were maintained at 18 °C for at least 8 d ays and then switched to 29 °C to induce transgenes. Lipid and sugar levels, cl imbing speed, and muscle morphology, gut morphology, and bloating phenotypes were all measured after switching to 29 °C for 8 days. For drug treatment, flies were transferred onto food containing inhibitors at day 0 (simultaneously with tumor induction) or day 4 (after tumor formation). MEK/ERK inhibitors PD0325901 (S1036) and Trametinib (S2673) were purchased from Selleckchem.
+ Open protocol
+ Expand
4

Evaluating MEK Inhibitor Cytotoxicity

Check if the same lab product or an alternative is used in the 5 most similar protocols
For drug treatment assays, cells were plated at a density of 2500 cells per well in a 96-well assay plate. The following day, cells were treated with the corresponding MEK1 inhibitors: selumetinib (AZD6244) S1008, trametinib (GSK1120212) S2673, and PD0325901 S1036 from Selleck Chemicals and refametinib (RDEA119) from Chemie Tek. Control wells were treated with dimethylsulfoxide (DMSO). Cell viability was assayed 6 days after drug treatment with CellTiter-Glo Luminescent Cell Viability Assay kit (Promega). Viability was normalized to DMSO controls. IC50 estimates were obtained using least-squares nonlinear regression on a standard 4-parameter logistic model.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!